Cantor Fitzgerald Predicts bluebird bio FY2025 Earnings

bluebird bio, Inc. (NASDAQ:BLUE - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of bluebird bio in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt forecasts that the biotechnology company will post earnings per share of ($23.60) for the year. The consensus estimate for bluebird bio's current full-year earnings is ($27.17) per share.

A number of other research analysts have also commented on BLUE. StockNews.com initiated coverage on bluebird bio in a report on Friday, December 20th. They set a "sell" rating for the company. Royal Bank of Canada reiterated a "sector perform" rating and set a $80.00 target price on shares of bluebird bio in a research note on Friday, November 15th. Wells Fargo & Company decreased their price target on shares of bluebird bio from $60.00 to $40.00 and set an "equal weight" rating on the stock in a research report on Wednesday, September 25th. JPMorgan Chase & Co. lowered shares of bluebird bio from a "neutral" rating to an "underweight" rating in a research report on Friday, November 15th. Finally, Barclays increased their target price on shares of bluebird bio from $2.00 to $40.00 and gave the company an "overweight" rating in a research note on Tuesday, December 31st. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $49.14.

bluebird bio Stock Performance

Shares of NASDAQ BLUE traded up $0.03 during trading hours on Wednesday, hitting $7.87. 176,987 shares of the company's stock were exchanged, compared to its average volume of 197,842. The company's 50-day moving average price is $8.13 and its 200-day moving average price is $11.97. bluebird bio has a 1-year low of $5.80 and a 1-year high of $38.40. The stock has a market capitalization of $76.50 million, a price-to-earnings ratio of -0.21 and a beta of 0.68. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.51 and a quick ratio of 0.33.

Hedge Funds Weigh In On bluebird bio

Several hedge funds have recently added to or reduced their stakes in the stock. Verition Fund Management LLC acquired a new stake in bluebird bio during the 3rd quarter worth $42,000. SG Americas Securities LLC lifted its holdings in shares of bluebird bio by 152.4% during the 3rd quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company's stock valued at $64,000 after purchasing an additional 74,185 shares in the last quarter. Captrust Financial Advisors lifted its holdings in shares of bluebird bio by 48.2% during the 3rd quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company's stock valued at $123,000 after purchasing an additional 77,293 shares in the last quarter. Barclays PLC grew its position in shares of bluebird bio by 273.7% in the 3rd quarter. Barclays PLC now owns 252,062 shares of the biotechnology company's stock valued at $130,000 after purchasing an additional 184,605 shares during the period. Finally, BNP Paribas Financial Markets increased its stake in bluebird bio by 2,270.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company's stock worth $193,000 after purchasing an additional 355,562 shares in the last quarter. Institutional investors and hedge funds own 87.43% of the company's stock.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.